58914-34-4

Basic information

• Product Name: 2-Formyl-5-(trifluoromethyl)phenol, 4-Formyl-3-hydroxybenzotrifluoride, 4-(Trifluoromethyl)salicylaldehyde
• Synonyms: 2-Formyl-5-(trifluoromethyl)phenol, 4-Formyl-3-hydroxybenzotrifluoride, 4-(Trifluoromethyl)salicylaldehyde;2-Hydroxy-4-(trifluoromethyl)benzaldehyde;2-Hydroxy-4-(trifluoromethyl)benzaldehyde 97%;4-Trifluoromethylsalicyaldehyde;2-Hydroxy-4-(trifluoromethyl)benzaldehyde97%;4-Formyl-3-hydroxybenzotrifluoride;2-Hydroxy-4-(trifluoromethyl)
• CAS NO: 58914-34-4
• Molecular Formula: C₈H₅F₃O₂
• Molecular Weight: 190.1193096
• Mol File: 58914-34-4.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 217.8±40.0 °C(Predicted)
• Appearance: /
• Density: 1.429±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 7.17±0.10(Predicted)
• CAS DataBase Reference: 2-Formyl-5-(trifluoromethyl)phenol, 4-Formyl-3-hydroxybenzotrifluoride, 4-(Trifluoromethyl)salicylaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Formyl-5-(trifluoromethyl)phenol, 4-Formyl-3-hydroxybenzotrifluoride, 4-(Trifluoromethyl)salicylaldehyde(58914-34-4)
• EPA Substance Registry System: 2-Formyl-5-(trifluoromethyl)phenol, 4-Formyl-3-hydroxybenzotrifluoride, 4-(Trifluoromethyl)salicylaldehyde(58914-34-4)

Safety Data

• Hazardous Substances Data: 58914-34-4(Hazardous Substances Data)

Usage

Uses

2-Hydroxy-4-(trifluoromethyl)benzaldehyde (cas# 58914-34-4) is used as a reactant in the preparation of flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease.

Upstream product

• 100-97-0 hexamethylenetetramine 
• 98-17-9 3-Trifluoromethylphenol 
• 89763-93-9 2-Fluoro-4-(trifluoromethyl)benzaldehyde 
• 50-00-0 formaldehyd 
• 328-90-5 4-trifluoromethylsalicylic acid 
• 1609405-64-2 2-methoxy-4-(trifluoromethyl)-1-vinylbenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 1352748-32-3 2-ethoxymethoxy-4-(trifluoromethyl)benzaldehyde 
• 1352748-31-2 1-ethoxymethoxy-3-(trifluoromethyl)benzene 
• 108-48-5 2,6-dimethylpyridine 
• 402-45-9 4-hydroxybenzotrifluoride 
• 132927-09-4 2-methoxy-4-(trifluoromethyl)benzaldehyde 
• 349-66-6 2-(hydroxymethyl)-5-(trifluoromethyl)phenol 
• 896732-43-7 2-(3-(trifluoromethyl)phenoxy)tetrahydro-2H-pyran 

Downstream Products

• 132927-09-4 2-methoxy-4-(trifluoromethyl)benzaldehyde 
• 1510865-19-6 2,3-diphenyl-8-(trifluoromethyl)benzo[b]oxepine 
• 334015-45-1 2-(methoxymethoxy)-4-(trifluoromethyl)benzaldehyde 
• 334018-36-9 2-ethoxy-4-(trifluoromethyl)benzaldehyde 

Relevant articles and documents

TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE

The invention provides a variety of compounds having the structure of Formula I and uses of such compounds for treatment of various indications, including cancer as well as methods of treatment involving such compounds are also provided. The uses of the compounds may specifically include: bladder cancer, cholangiocarcinoma; colorectal cancer; diffuse large B-cell lymphoma (DLBC); liver cancer; ovarian cancer; thymoma; thyroid cancer; clear cell renal cell carcinoma (CCRCC); chromophobe renal cell carcinoma (ChRCC); prostate cancer; breast cancer; uterine cancer; pancreatic cancer; cervical cancer; uveal melanoma; acute myeloid leukemia (AML); head and neck cancer; small cell lung cancer (SCLC); lung adenocarcinoma sarcoma; mesothelioma; adenoid cystic carcinoma (ACC), sarcoma; testicular germ cell cancer; uterine cancer; pheochromocytoma and paraganglioma (PCPG); melanoma; glioma; glioblastoma multiforme; T-cell Acute Lymphoblastic Leukemia; T-cell Lympohoma, medulloblastoma; and neuroblastoma.

NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS

The present invention is concerned with novel substituted pyrido-piperazinone derivatives of Formula (I) wherein R1, R2, R3, R4, R5, L, Z and X have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

MAGL INHIBITORS

Provided herein are spirocyclic and fused bicyclic carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.